What changed
On September 25, NIH published a request for information on a draft policy that would require researchers conducting NIH-supported clinical research to share plain-language, summary-level study results with participants. The notice says NIH's existing dissemination efforts have largely focused on the scientific community rather than direct return to participants. Comments close October 26. That distinction matters because the draft covers NIH-supported clinical research, including clinical trials, across the listed extramural and intramural settings. NIH defines summary-level results as concise overviews prepared after the data are compiled and analyzed. They include the study's objective, conduct, methodology as appropriate, aggregate findings, relevance, limitations, and potential implications. The notice separates those summaries from participant-specific results such as individual lab results.
The proposed timing depends on the type of study. Clinical trials would generally share results no later than one year after the primary completion date or the applicable ClinicalTrials.gov reporting date, whichever is later. Non-trial extramural research would share by the end of the performance period when the analysis is complete, or provide participants and NIH with a status update. Intramural studies would provide annual status updates under the proposed schedule.
NIH also proposes an exception route when sharing is justifiably inappropriate, subject to agency approval. If unforeseen circumstances later make sharing impossible, participants would receive an explanation, with the change subject to NIH approval and IRB approval when necessary. Researchers would confirm to NIH that results or a status update were provided.
Why it matters
A study can reach a journal, a public registry, or a scientific database while the people who participated still lack a direct and understandable return path. That is an editorial reading of the operational gap described by NIH, rather than a finding that researchers generally withhold results or violate an existing duty. That gap is why the proposed return route belongs in study planning. A team would need to know which aggregate findings will be shared, when participants will receive them, which communication method fits the study population, how an exception or delay will be handled, and what record will confirm the handoff. The draft encourages researchers to plan with participants, IRBs, and institutional officials.
That plan needs a second writing audience. NIH is asking what participants find useful, which formats they prefer, how primary and secondary results should be handled, and what costs or infrastructure the work requires. Technical accuracy alone cannot make a summary understandable.
Watch next
Watch the public comments for evidence about participant preferences, practical costs, and cases where sharing may be inappropriate or impossible. Then watch any final policy for changes to scope, deadlines, exception criteria, and the proposed six-month lead-in. Supplemental guidance could determine how researchers handle culturally and contextually appropriate language, caregivers, and proof that participants were offered a usable result or status update.
Source
- Federal Register: Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
- Official GovInfo PDF
- NIH public comment form
This is a request for information on a draft policy, not a final or currently effective requirement. Final scope, timing, exceptions, and guidance may change. Summary-level results are aggregate and do not provide individualized findings or medical interpretation. This card is informational and does not offer medical, legal, grant-compliance, or research-ethics advice.
